Semaglutide dosing & administration
The revolutionary once-weekly GLP-1 medication that helps your body feel full faster and longer, leading to significant weight loss while also protecting your heart—FDA approved and backed by some of the largest clinical trials in obesity medicine history.
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Dosing
How much do I take?
Subcutaneous: A small injection into the fatty layer just under the skin — the same way insulin is given.
Bioavailability High — most of the dose reaches your bloodstream, just more gradually than an IV.
Titration schedule
0.25 mg
Frequency
Once weekly
Duration
4 weeks
This is the starter dose to help your body adjust. It does not lower blood sugar much on its own, so it is only used for the first 4 weeks before stepping up [5].
0.5-1 mg
Frequency
Once weekly
Duration
At least 4 weeks at each step
After the starter month, the dose goes up to 0.5 mg, and can rise to 1 mg if more blood sugar control is needed. Wait at least 4 weeks before each increase [5].
2-2.4 mg
Frequency
Once weekly
Duration
Ongoing/maintenance
The highest weekly doses. 2 mg is the maximum for diabetes (Ozempic) [5]; up to 2.4 mg is used for weight management (Wegovy) after a slower titration.
Timing
Best time to take
Choose any day of the week that works for your schedule and stick with it. Many people prefer Sunday or Monday to make it easy to remember. Take it at roughly the same time each week, though the exact hour doesn't matter much due to the long half-life [5][7].
With food?
Semaglutide injections can be taken with or without food—it doesn't affect absorption. However, because the medication slows stomach emptying, eating smaller meals will help reduce nausea. The oral version (Rybelsus) MUST be taken on an empty stomach with a small amount of water.
If stacking
Semaglutide is typically used as a standalone weight management therapy. If using with other diabetes medications, especially insulin or sulfonylureas, doses of those medications may need to be reduced to prevent low blood sugar. Always coordinate with your healthcare provider [5][7].
Adjusting your dose
Increase if
- You've tolerated the current dose for 4+ weeks without significant GI issues
- Weight loss has plateaued and you haven't reached target dose
- Blood sugar targets aren't being met (for diabetes patients)
- Your healthcare provider recommends progression based on your response
Decrease if
- Nausea, vomiting, or diarrhea are severe and persistent
- You're unable to eat enough to maintain basic nutrition
- You experience signs of dehydration from GI symptoms
- Side effects significantly impact your quality of life
Signs of right dose
- Steady weight loss of 1-2 pounds per week
- Feeling satisfied with smaller portions
- Reduced food cravings and thoughts about food
- Manageable or no GI side effects
Administration
How do I use it?
Reconstitution
What you need
Injection
Route
Subcutaneous injection (into the fatty tissue just under the skin)—quick, relatively painless, and can be self-administered at home
Best sites
Storage
Before reconstitution
Store new, unopened pens in the refrigerator at 36-46°F (2-8°C). Do not freeze—freezing destroys the medication. Keep in original carton to protect from light. If needed, unopened pens can be stored at room temperature (up to 86°F/30°C) for up to 28 days before first use.
After reconstitution
After first use, pens can be stored in the refrigerator or at room temperature up to 86°F (30°C). Use within 56 days of first injection. Always replace the pen cap after use to protect from light. Never store with needle attached.
Signs of degradation — discard the vial
Sample daily schedule
Same day each week (e.g., every Sunday morning)
As prescribed (0.25mg to 2.4mg depending on phase) injection
Site: Rotate between abdomen, thigh, and arm weekly
Pick a day you'll remember. Many people choose a weekend day so they can rest if they experience nausea. The injection takes less than 30 seconds once you get the hang of it. If you miss a dose by less than 5 days, take it as soon as you remember. If more than 5 days late, skip that dose and take the next one on your regular day.
Safety
Is it safe?
Side effects
Commonly reported: Nausea, Constipation or Diarrhea, Decreased Appetite, Vomiting
Less common: Gallbladder Problems, Hair Loss (Telogen Effluvium)
Stop and seek help if
- Severe or persistent nausea and vomiting that prevents adequate nutrition despite dose adjustments
- Signs of pancreatitis—severe abdominal pain radiating to the back
- Allergic reaction—rash, itching, swelling, difficulty breathing
- Signs of thyroid tumors—neck lump, hoarseness, trouble swallowing
- Pregnancy or planning to become pregnant (stop at least 2 months before conception)
- Severe kidney problems or dehydration from GI symptoms
- Your healthcare provider recommends discontinuation
Semaglutide is a prescription medication that should only be started, adjusted, or stopped under medical supervision. This information is educational and does not replace professional medical advice. Stopping suddenly is generally safe, but discuss any changes with your healthcare provider.
Flagged pairings
- Other GLP-1 Agonists (liraglutide, tirzepatide) — Never combine GLP-1 medications—they work through the same mechanism and combining would increase side effects without additional benefit.
- Insulin — Semaglutide enhances insulin's blood sugar-lowering effect. Insulin doses typically need to be reduced 20-50% when starting semaglutide to prevent hypoglycemia. Work closely with your doctor.
- Sulfonylureas (glipizide, glyburide) — High risk of hypoglycemia when combined. Sulfonylurea dose usually needs reduction. Monitor blood sugar closely.
Published research
What the studies show
Wilding JPH, Batterham RL, Calanna S, et al. · 2021
This landmark trial proved semaglutide's effectiveness for weight loss. Participants lost an average of 14.9% of their body weight over 68 weeks (about 33 pounds), compared to just 2.4% with placebo. Over half lost more than 15% of their body weight—results previously only seen with surgery.
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. · 2023
This massive trial of 17,604 people proved semaglutide reduces heart attacks, strokes, and cardiovascular death by 20% in people with obesity and heart disease—even without diabetes. This was the first time a weight loss medication showed direct cardiovascular benefits.
Weiskirchen R, Lonardo A · 2025
This comprehensive review traced semaglutide's development from laboratory discovery to clinical breakthrough, documenting its expanding role beyond diabetes into obesity treatment and metabolic liver disease—cementing its status as a transformative therapy.
Mondoh A, Crotty M, le Roux CW · 2025
Head-to-head comparisons show both medications are highly effective, with tirzepatide producing somewhat greater weight loss in some studies. However, semaglutide has more long-term safety data and the SELECT cardiovascular outcomes trial supporting its use.
Novo Nordisk / U.S. FDA · 2025
Subcutaneous semaglutide is started at 0.25 mg once weekly for 4 weeks, then increased to 0.5 mg, then 1 mg, then up to a maximum of 2 mg once weekly, with at least 4 weeks between increases.
Novo Nordisk / U.S. FDA · 2024
Oral semaglutide is started at 3 mg once daily for 30 days (initiation dose, not effective for glucose control), then increased to 7 mg once daily, and may be increased to a maximum of 14 mg once daily. Taken on an empty stomach with up to 4 oz water, 30 minutes before food or other medicines.
Novo Nordisk / U.S. FDA · 2024
US label for semaglutide 2.4 mg for chronic weight management and cardiovascular risk reduction. Carries the boxed warning for rodent thyroid C-cell tumors and contraindication in personal or family history of MTC or MEN 2. Indicated at BMI 30 or greater, or 27 or greater with at least one weight-related comorbidity. Titration is 0.25 mg weekly for 4 weeks then escalation every 4 weeks to a 2.4 mg maintenance dose, explicitly 'to minimize gastrointestinal adverse reactions.' Adverse reactions in 2,116 adults: nausea 44%, diarrhea 30%, vomiting 24%, constipation 24%, abdominal pain 20%, hair loss 3%. Cholelithiasis 1.6% and cholecystitis 0.6% versus 0.7% and 0.2% on placebo; acute pancreatitis adjudicated in 4 patients (0.2 per 100 patient-years). Semaglutide is 94% homologous to human GLP-1, modified at position 8 against DPP-4 degradation and acylated at lysine 26 with a C18 fatty di-acid via a hydrophilic spacer; albumin binding exceeds 99% and the elimination half-life is approximately 1 week. It delays gastric emptying, lowers calorie intake, and loses more fat mass than lean mass. Dose may be given any time of day with or without food; concomitant insulin or insulin secretagogue may require dose reduction.
Davies M, Færch L, Jeppesen OK, et al. · 2021
In 1,210 adults with overweight or obesity and type 2 diabetes, semaglutide 2.4 mg once weekly reduced body weight by 9.6% at 68 weeks versus 3.4% with placebo, and 68.8% versus 28.5% achieved at least 5% weight loss. Gastrointestinal adverse events, mostly mild to moderate, occurred in 63.5% of the 2.4 mg group.
Wadden TA, Bailey TS, Billings LK, et al. · 2021
In 611 adults with overweight or obesity, semaglutide 2.4 mg weekly plus intensive behavioral therapy reduced body weight by 16.0% at 68 weeks versus 5.7% with placebo; 55.8% versus 13.2% lost at least 15% of baseline weight.
Rubino D, Abrahamsson N, Davies M, et al. · 2021
After a 20-week run-in to semaglutide 2.4 mg, 803 adults were randomised to continue or switch to placebo. Continuing semaglutide produced a further 7.9% weight loss over 48 weeks while switching to placebo produced a 6.9% regain, a difference of 14.8 percentage points.
Wilding JPH, Batterham RL, Davies M, et al. · 2022
One year after semaglutide 2.4 mg and lifestyle intervention were withdrawn, participants had regained 11.6 of the 17.3 percentage points of weight they had lost, about two-thirds of the prior weight loss, and cardiometabolic improvements reverted toward baseline.
Lau J, Bloch P, Schäffer L, et al. · 2015
Semaglutide carries two amino acid substitutions relative to human GLP-1 (Aib at position 8 and Arg at position 34) and is derivatised at lysine 26 with a fatty di-acid linked through a spacer. The Aib8 substitution secures stability against metabolic degradation and the acylation raises albumin affinity, which is the protraction mechanism behind once-weekly dosing.
Secher A, Jelsing J, Baquero AF, et al. · 2014
In the arcuate nucleus, a GLP-1 analogue was internalised in neurons expressing proopiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART). Electrophysiology showed GLP-1 directly stimulates POMC/CART neurons and indirectly inhibits neurotransmission in neuropeptide Y (NPY) and agouti-related peptide (AgRP) neurons via GABA-dependent signalling.
Bjerre Knudsen L, Madsen LW, Andersen S, et al. · 2010
The GLP-1 receptor was localised to rodent thyroid C-cells, where agonists stimulated calcitonin release and C-cell hyperplasia. Humans and cynomolgus monkeys had low GLP-1 receptor expression in thyroid C-cells and no calcitonin release or adenylate cyclase activation in response to GLP-1 receptor agonists, delineating a species-specific difference in the thyroid.
Pasternak B, Wintzell V, Hviid A, et al. · 2024
Across 145,410 GLP-1 receptor agonist users and 291,667 DPP-4 inhibitor users in Denmark, Norway and Sweden, GLP-1 receptor agonist use was not associated with increased thyroid cancer risk (hazard ratio 0.93, 95% CI 0.66 to 1.31) over a mean 3.9 years of follow-up; the hazard ratio for medullary thyroid cancer was 1.19 (0.37 to 3.86).
Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M · 2023
In a population-based cohort of patients using GLP-1 receptor agonists for weight loss, the incidence of pancreatitis with semaglutide was 4.6 per 1000 person-years, versus 7.9 for liraglutide and 1.0 for bupropion-naltrexone. Biliary disease was 11.7 and gastroparesis 9.1 per 1000 person-years with semaglutide.
Burke OM, Sa B, Alvarez Cespedes D, Tosti A · 2025
Hair loss in the form of telogen effluvium has been observed with GLP-1 receptor agonists and is potentially linked to the rapid weight loss these drugs produce rather than to a direct drug effect on the follicle.
Eisa N, Barood O · 2026
Across 20 randomised trials and 15,782 participants, lean mass made up 25% to 39% of total weight lost with incretin agonists: 35.2% for semaglutide, 25.4% for tirzepatide and 26.8% for liraglutide. Lifestyle intervention alone was comparable at 26.2%, while lifestyle plus resistance training was the most favourable at 17.5%.
Hendershot CS, Bremmer MP, Paladino MB, et al. · 2025
In a 9-week phase 2 randomised trial in 48 adults with alcohol use disorder, low-dose semaglutide reduced laboratory alcohol self-administration, drinks per drinking day and weekly alcohol craving relative to placebo, and predicted greater reductions in heavy drinking over time.
Wharton S, Freitas P, Hjelmesæth J, et al. · 2025
A 7.2 mg once-weekly maintenance dose of subcutaneous semaglutide was tested against 2.4 mg and placebo in 1,407 adults with obesity over 72 weeks, producing 18.7% weight loss versus 15.6% with 2.4 mg and 3.9% with placebo. Gastrointestinal adverse events and dysaesthesia were more frequent at 7.2 mg.
Pratley RE, Crowley MJ, Gislum M, et al. · 2021
Across PIONEER 3-5, 7 and 8 (2,836 patients), semaglutide lowered HbA1c by 1.0 to 1.5 percentage points and body weight by 2.2 to 5.0 kg regardless of which background glucose-lowering medications patients were taking, and total daily insulin dose decreased in patients receiving semaglutide.
Verma S, Bhatta M, Davies M, et al. · 2022
Semaglutide 2.4 mg reduced serum C-reactive protein at week 68 versus placebo by 44% in STEP 1, 39% in STEP 2 and 48% in STEP 3, irrespective of baseline BMI, body weight or glycaemic status. Reductions tracked with weight loss, waist circumference, fasting glucose, fasting insulin and HOMA-IR, and more semaglutide-treated participants moved into a lower CRP-defined cardiovascular risk category, suggesting an anti-inflammatory role in obesity.
Studied for
Conditions Semaglutide has been researched in
Want the full picture?
The complete Semaglutide research profile: mechanism of action, clinical studies, effectiveness timeline, and FAQ.